PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
5.62%
Net income growth under 50% of CRVO's 18.65%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
3.20%
Some D&A expansion while CRVO is negative at -2.83%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
22.07%
Less SBC growth vs. CRVO's 63.99%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
81.65%
Well above CRVO's 117.55% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.82%
AP growth well above CRVO's 100.91%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
28.44%
Lower 'other working capital' growth vs. CRVO's 130.31%. David Dodd would see fewer unexpected short-term demands on cash.
-17.77%
Negative yoy while CRVO is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
18.75%
Operating cash flow growth at 50-75% of CRVO's 35.72%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
-1425.00%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1425.00%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Both yoy lines negative, with CRVO at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.